Reports of Biochemistry
and Molecular Biology
Wed, Jul 30, 2025
[Archive]
Volume 13, Issue 4 (Vol.13 No.4 Jan 2025)
rbmb.net 2025, 13(4): 484-494 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Behmardi A, Zolghadr L, Rajaei F, Gholamzadeh Khoei S, Gheibi N. Protective Effects of Liposomal Vitamin C on SARS-CoV-2 Target Viral Entry Genes in Renal Cells. rbmb.net 2025; 13 (4) :484-494
URL: http://rbmb.net/article-1-1546-en.html
URL: http://rbmb.net/article-1-1546-en.html
Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran.
Abstract: (285 Views)
Background: The kidneys are a potential target for SARS-CoV-2 infection. Ascorbic acid (vitamin C) has been shown to play an important role in reducing the symptoms of SARS-CoV-2. Recently liposomal drug delivery platforms have demonstrated promising results in enhancing the effectiveness of various therapeutics including infectious diseases. In this study, we designed a liposomal delivery system containing vitamin C to evaluate its antiviral efficacy in COVID-19, focusing on its effects on viral entry gene expression in Vero cells.
Methods: Vitamin C was loaded into a liposome made up of hydrogenated soybean phosphatidylcholine, cholesterol, and 1,2‐distearoyl‐sn‐glycero‐3 phosphoethanolamine‐N‐[methoxy (polyethylene glycol)‐2000], and their physicochemical properties were assessed. Next, the cytotoxicity of free and liposomal vitamin C on the survival of the Vero cell line was evaluated using the MTT assay. In addition, the expression of viral entry genes, angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2), key mediators of SARS-CoV-2 entry into kidney cells, was investigated using RTq-PCR.
Results: Liposomes were successfully loaded with vitamin C, achieving an encapsulation efficiency of 88.03%. The liposomal vitamin C formulation exhibited a brilliant surface morphology as observed by SEM. Both free and liposomal forms of vitamin C showed cytotoxic effects at higher concentrations. Moreover, both forms downregulated the expression of viral entry genes, although the liposomal form showed superior inhibitory performance compared to the free form.
Conclusion: The study suggests liposomal vitamin C as a safe, effective treatment for COVID-19 by targeting viral entry genes in kidney cells, protecting them from viral damage and inflammation.
Methods: Vitamin C was loaded into a liposome made up of hydrogenated soybean phosphatidylcholine, cholesterol, and 1,2‐distearoyl‐sn‐glycero‐3 phosphoethanolamine‐N‐[methoxy (polyethylene glycol)‐2000], and their physicochemical properties were assessed. Next, the cytotoxicity of free and liposomal vitamin C on the survival of the Vero cell line was evaluated using the MTT assay. In addition, the expression of viral entry genes, angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2), key mediators of SARS-CoV-2 entry into kidney cells, was investigated using RTq-PCR.
Results: Liposomes were successfully loaded with vitamin C, achieving an encapsulation efficiency of 88.03%. The liposomal vitamin C formulation exhibited a brilliant surface morphology as observed by SEM. Both free and liposomal forms of vitamin C showed cytotoxic effects at higher concentrations. Moreover, both forms downregulated the expression of viral entry genes, although the liposomal form showed superior inhibitory performance compared to the free form.
Conclusion: The study suggests liposomal vitamin C as a safe, effective treatment for COVID-19 by targeting viral entry genes in kidney cells, protecting them from viral damage and inflammation.
Type of Article: Original Article |
Subject:
Microbiology
Received: 2024/12/29 | Accepted: 2025/03/26 | Published: 2025/07/30
Received: 2024/12/29 | Accepted: 2025/03/26 | Published: 2025/07/30
References
1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W,W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Erratum in: Nature. 2020;588(7836):E6. [DOI:10.1038/s41586-020-2951-z] [PMID] []
2. Rostami-Far Z, Rahmani K, Mansouri K, Khadem Erfan MB, Shaveisi-Zadeh F, Nikkhoo B. Genetic Regulation of Interleukin-6 and Interleukin-10 in COVID-19 Infection. Rep Biochem Mol Biol. 2023;12(2):284-293. [DOI:10.61186/rbmb.12.2.284] [PMID] []
3. Liakopoulos V, Roumeliotis S, Papachristou S, Papanas N. COVID-19 and the kidney: time to take a closer look. Int Urol Nephrol. 2022;54(5):1053-1057. [DOI:10.1007/s11255-021-02976-7] [PMID] []
4. Rai V. COVID-19 and Kidney: The Importance of Follow-Up and Long-Term Screening. Life (Basel, Switzerland). 2023;13(11):2137. [DOI:10.3390/life13112137] [PMID] []
5. Kahar LA. Interleukin-6 and Procalcitonin as Potential Predictors of Acute Kidney Injury Occurrence in Patients with Sepsis. Rep Biochem Mol Biol. 2024;13(2):144-153. [DOI:10.61186/rbmb.13.2.144] [PMID] []
6. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nature Reviews Molecular Cell Biology. 2022;23(1):3-20. [DOI:10.1038/s41580-021-00418-x] [PMID] []
7. Musavi H, Abazari O, Barartabar Z, Kalaki-Jouybari F, Hemmati-Dinarvand M, Esmaeili P, et al. The benefits of Vitamin D in the COVID-19 pandemic: biochemical and immunological mechanisms. Arch Physiol Biochem. 2023;129(2):354-62. [DOI:10.1080/13813455.2020.1826530] [PMID]
8. Mizuiri S, Ohashi Y. ACE and ACE2 in kidney disease. World J Nephrol. 2015;4(1):74-82. [DOI:10.5527/wjn.v4.i1.74] [PMID] []
9. Soleimani M. Acute Kidney Injury in SARS-CoV-2 Infection: Direct Effect of Virus on Kidney Proximal Tubule Cells. Int J Mol Sci. 2020;21(9):3275. [DOI:10.3390/ijms21093275] [PMID] []
10. Ahmadian E, Hosseiniyan Khatibi SM, Razi Soofiyani S, Abediazar S, Shoja MM, Ardalan M, Zununi Vahed S. Covid-19 and kidney injury: Pathophysiology and molecular mechanisms. Rev Med Virol. 2021;31(3):e2176. [DOI:10.1002/rmv.2176] [PMID] []
11. Holford P, Carr AC, Jovic TH, Ali SR, Whitaker IS, Marik PE, Smith AD. Vitamin C-An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19. Nutrients. 2020;12(12):3760. [DOI:10.3390/nu12123760] [PMID] []
12. Hemilä H, de Man AME. Vitamin C and COVID-19. Front Med (Lausanne). 2021;7:559811. [DOI:10.3389/fmed.2020.559811] [PMID] []
13. Fisher BJ, Seropian IM, Kraskauskas D, Thakkar JN, Voelkel NF, Fowler AA 3rd, Natarajan R. Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury. Crit Care Med. 2011 Jun;39(6):1454-60. [DOI:10.1097/CCM.0b013e3182120cb8] [PMID]
14. Fisher BJ, Kraskauskas D, Martin EJ, Farkas D, Wegelin JA, Brophy D, et al. Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid. Am J Physiol Lung Cell Mol Physiol. 2012;303(1):L20-32. [DOI:10.1152/ajplung.00300.2011] [PMID]
15. Li W, Maeda N, Beck MA. Vitamin C deficiency increases the lung pathology of influenza virus-infected gulo-/- mice. J Nutr. 2006;136(10):2611-6. [DOI:10.1093/jn/136.10.2611] [PMID]
16. Arvinte C, Singh M, Marik PE. Serum Levels of Vitamin C and Vitamin D in a Cohort of Critically Ill COVID-19 Patients of a North American Community Hospital Intensive Care Unit in May 2020: A Pilot Study. Med Drug Discov. 2020;8:100064. [DOI:10.1016/j.medidd.2020.100064] [PMID] []
17. Chiscano-Camón L, Ruiz-Rodriguez JC, Ruiz-Sanmartin A, Roca O, Ferrer R. Vitamin C levels in patients with SARS-CoV-2-associated acute respiratory distress syndrome. Crit Care. 2020;24(1):522. [DOI:10.1186/s13054-020-03249-y] [PMID] []
18. Ma S, Sun S, Li J, Fan Y, Qu J, Sun L, et al. Single-cell transcriptomic atlas of primate cardiopulmonary aging. Cell Res. 2021;31(4):415-32. [DOI:10.1038/s41422-020-00412-6] [PMID] []
19. Purpura M, Jäger R, Godavarthi A, Bhaskarachar D, Tinsley GM. Liposomal delivery enhances absorption of vitamin C into plasma and leukocytes: a double-blind, placebo-controlled, randomized trial. Eur J Nutr. 2024;63(8):3037-3046. [DOI:10.1007/s00394-024-03487-8] [PMID] []
20. Khuntawee W, Amornloetwattana R, Vongsangnak W, Namdee K, Yata T, Karttunen M, Wong-Ekkabut J. In silico and in vitro design of cordycepin encapsulation in liposomes for colon cancer treatment. RSC Adv. 2021;11(15):8475-8484. [DOI:10.1039/D1RA00038A] [PMID] []
21. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A. 1996;93(8):3704-9. [DOI:10.1073/pnas.93.8.3704] [PMID] []
22. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A. 1996;93(8):3704-9. [DOI:10.1073/pnas.93.8.3704] [PMID] []
23. Prantl L, Eigenberger A, Gehmert S, Haerteis S, Aung T, Rachel R, et al. Enhanced Resorption of Liposomal Packed Vitamin C Monitored by Ultrasound. J Clin Med. 2020;9(6):1616. [DOI:10.3390/jcm9061616] [PMID] []
24. Sabaghi Y, PourFarzad F, Zolghadr L, Bahrami A, Shojazadeh T, Farasat A, Gheibi N. A nano-liposomal carrier containing p-coumaric acid for induction of targeted apoptosis on melanoma cells and kinetic modeling. Biochem Biophys Res Commun. 2024;690:149219. [DOI:10.1016/j.bbrc.2023.149219] [PMID]
25. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-23.
26. Paarakh MP, Jose PA, Setty C, Peter Christoper. Int J Pharm Res Technol. Release kinetics-concepts and applications. 2018;8(1):12-20.
27. Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, et al. Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient. bioRxiv [Preprint]. 2020:2020.03.02.972935. [DOI:10.1101/2020.03.02.972935]
28. Gkogkou E, Barnasas G, Vougas K, Trougakos IP. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators. Redox Biol. 2020;36:101615. [DOI:10.1016/j.redox.2020.101615] [PMID] []
29. Pamunuwa GK, Karunaratne DNJJoFQ. Liposomal Delivery of Plant Bioactives Enhances Potency in Food Systems: A Review. J Food Quality. 2022;2022(1):5272592. [DOI:10.1155/2022/5272592]
30. Rs N, Reddy MVNJ, Batra S, Srivastava SK, Syal K. Vitamin C and its therapeutic potential in the management of COVID19. Clin Nutr ESPEN. 2022;50:8-14. [DOI:10.1016/j.clnesp.2022.05.026] [PMID] []
31. Wang Y, Mackenzie B, Tsukaguchi H, Weremowicz S, Morton CC, Hediger MA. Human vitamin C (L-ascorbic acid) transporter SVCT1. Biochem Biophys Res Commun. 2000;267(2):488-94. [DOI:10.1006/bbrc.1999.1929] [PMID]
32. Liu P, Chen G, Zhang JJM. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules. 2022;27(4):1372. [DOI:10.3390/molecules27041372] [PMID] []
33. Tavill AS; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. Diagnosis and management of hemochromatosis. Hepatology. 2001;33(5):1321-8. [DOI:10.1053/jhep.2001.24783] [PMID]
34. Thomas LD, Elinder CG, Tiselius HG, Wolk A, Akesson A. Ascorbic acid supplements and kidney stone incidence among men: a prospective study. JAMA Intern Med. 2013;173(5):386-8. [DOI:10.1001/jamainternmed.2013.2296] [PMID]
35. Gkogkou E, Barnasas G, Vougas K, Trougakos IP. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators. Redox Biol. 2020;36:101615. [DOI:10.1016/j.redox.2020.101615] [PMID] []
36. Pan XW, Xu D, Zhang H, Zhou W, Wang LH, Cui XG. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med. 2020;46(6):1114-1116. [DOI:10.1007/s00134-020-06026-1] [PMID] []
37. Simões E Silva AC, Teixeira MM. ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. Pharmacol Res. 2016;107:154-162. [DOI:10.1016/j.phrs.2016.03.018] [PMID]
38. Ivanov V, Goc A, Ivanova S, Niedzwiecki A, Rath M. Inhibition of ACE2 Expression by Ascorbic Acid Alone and its Combinations with Other Natural Compounds. Infect Dis (Auckl). 2021;14:1178633721994605. [DOI:10.1177/1178633721994605] [PMID] []
39. Zuo Y, Zheng Z, Huang Y, He J, Zang L, Ren T, et al. Vitamin C promotes ACE2 degradation and protects against SARS‐CoV‐2 infection. EMBO reports. 2023;24(4):e56374. [DOI:10.15252/embr.202256374] [PMID] []
40. Reus P, Guthmann H, Uhlig N, Agbaria M, Issmail L, Eberlein V, et al. Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system. J Control Release. 2023;364:654-671. [DOI:10.1016/j.jconrel.2023.10.050] [PMID]
41. Que H, Hong W, Lan T, Zeng H, Chen L, Wan D, et al. Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment. Signal Transduct Target Ther. 2022;7(1):399. [DOI:10.1038/s41392-022-01283-6] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
